Adamu Aishatu L, Gadanya Muktar A, Abubakar Isa S, Jibo Abubakar M, Bello Musa M, Gajida Auwalu U, Babashani Musa M, Abubakar Ibrahim
Department of Community Medicine, College of Health Sciences, Bayero University Kano, Kano, Nigeria.
Department of Community Medicine, Aminu Kano Teaching Hospital, Kano, Nigeria.
BMC Infect Dis. 2017 Feb 23;17(1):170. doi: 10.1186/s12879-017-2249-4.
Tuberculosis (TB) remains a leading cause of death in much of sub-Saharan Africa despite available effective treatment. Prompt initiation of TB treatment and access to antiretroviral therapy (ART) remains vital to the success of TB control. We assessed time to mortality after treatment onset using data from a large treatment centre in Nigeria.
We analysed a retrospective cohort of TB patients that commenced treatment between January 2010 and December 2014 in Aminu Kano Teaching Hospital. We estimated mortality rates per person-months at risk (pm). Cox proportional hazards model was used to determine risk factors for mortality.
Among 1,424 patients with a median age of 36.6 years, 237 patients (16.6%) died after commencing TB treatment giving a mortality rate of 3.68 per 100 pm of treatment in this cohort. Most deaths occurred soon after treatment onset with a mortality rate of 37.6 per 100 pm in the 1 week of treatment. Risk factors for death were being HIV-positive but not on anti-retroviral treatment (ART) (aHR 1.39(1 · 04-1 · 85)), residence outside the city (aHR 3 · 18(2.28-4.45)), previous TB treatment (aHR 3.48(2.54-4.77)), no microbiological confirmation (aHR 4.96(2.69-9.17)), having both pulmonary and extra-pulmonary TB (aHR 1.45(1.03-2.02), and referral from a non-programme linked clinic/centre (aHR 3.02(2.01-4.53)).
We attribute early deaths in this relatively young cohort to delay in diagnosis and treatment of TB, inadequate treatment of drug-resistant TB, and poor ART access. Considerable expansion and improvement in quality of diagnosis and treatment services for TB and HIV are needed to achieve the sustainable development goal of reducing TB deaths by 95% by 2035.
尽管有有效的治疗方法,但结核病(TB)仍是撒哈拉以南非洲大部分地区的主要死因。及时开始结核病治疗并获得抗逆转录病毒疗法(ART)对于结核病控制的成功仍然至关重要。我们使用尼日利亚一个大型治疗中心的数据评估了治疗开始后的死亡时间。
我们分析了2010年1月至2014年12月在阿米努·卡诺教学医院开始治疗的结核病患者的回顾性队列。我们估计了每人每月的死亡风险率(pm)。采用Cox比例风险模型确定死亡的危险因素。
在1424名中位年龄为36.6岁的患者中,237名患者(16.6%)在开始结核病治疗后死亡,该队列中每100个治疗月的死亡率为3.68。大多数死亡发生在治疗开始后不久,治疗第1周的死亡率为每100个治疗月37.6。死亡的危险因素包括HIV阳性但未接受抗逆转录病毒治疗(ART)(风险比1.39(1.04 - 1.85))、居住在城外(风险比3.18(2.28 - 4.45))、既往有结核病治疗史(风险比3.48(2.54 - 4.77))、无微生物学确诊(风险比4.96(2.69 - 9.17))、同时患有肺结核和肺外结核(风险比1.45(1.03 - 2.02))以及从非项目关联诊所/中心转诊(风险比3.02(2.01 - 4.53))。
我们将这个相对年轻队列中的早期死亡归因于结核病诊断和治疗的延迟、耐多药结核病治疗不足以及抗逆转录病毒疗法获取困难。为实现到2035年将结核病死亡人数减少95%的可持续发展目标,需要大幅扩大和改善结核病及艾滋病的诊断和治疗服务质量。